Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
U.S. stocks broke their three-day losing streak today, with the S&P 500 gaining 0.8%. The narrower, price-weighted Dow Jones Industrial Average (DJINDICES: ^DJI ) gained 0.7%, closing above 16,000 for the first time.
Last week, I highlighted�three reasons why Warren Buffett bought ExxonMobil (NYSE: XOM ) for Berkshire Hathaway's (NYSE: BRK-B ) equity portfolio. (He did so in size, too -- the position was valued at $3.4 billion at the end of the third quarter.) This week, short-seller Jim Chanos, who famously bet against failed energy company Enron, offered a few reasons of his own -- for steering clear of the shares, characterizing ExxonMobil as a "value trap." Is Mr. Chanos right? Did the Oracle of Omaha just make a monumental mistake?
At the Reuters Global Investment Outlook on Tuesday, Chanos described his negative thesis regarding the energy supermajor's business and its stock:
Top 10 Performing Companies To Watch In Right Now: Baxter International Inc. (BAX)
Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: BioScience, Medication Delivery, and Renal. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs; intravenous nutrition products; infusion pumps; and inhalation anesthetics. It also offers products and services related to pha rmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease or irreversible kidney failure. It manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes product for hemodialysis, which is conducted in a hospital or clinic. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors? offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is based in Deerfield, Illinois.
Advisors' Opinion:- [By Jon C. Ogg]
Baxter International Inc. (NYSE: BAX) was added to the Conviction Buy list with an $86 price target at Goldman Sachs.
Finisar Corp. (NASDAQ: FNSR) was raised to Outperform from Market Perform�by Raymond James after raising guidance.
Hot Warren Buffett Companies To Own In Right Now: Boston Therapeutics Inc (BTHE)
Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.
SUGARDOWN
The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.
PAZ320
PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.
IPOXYN
The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.
Advisors' Opinion:- [By CRWE]
Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).
Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.
Hot Warren Buffett Companies To Own In Right Now: Alumina Ltd (AWC)
Alumina Limited, through its 40% equity interest in Alcoa World Alumina and Chemicals, engages in the bauxite mining, alumina refining, and aluminum smelting businesses. It has interests in eight alumina refineries and eight bauxite mines, as well as operates two aluminum smelters in Victoria, Australia. The company also owns interests in a network of mines, refineries, and smelters in the United States, Guinea, Suriname, Jamaica, Brazil, and Spain. In addition, it owns and operates a shipping operation that transports alumina, aluminum, and raw materials worldwide. The company, formerly known as WMC Limited, was founded in 1970 and is based in Southbank, Australia.
Advisors' Opinion:- [By Tim Melvin]
One such company is Alumina Limited (NYSE ADR: AWC), an Australian aluminum company.
Alumina, which mines and refines aluminum, operates eight refineries and two aluminum smelters and owns or has interest in seven mining operations. It has a shipping operation that transports aluminum-related raw materials.
Hot Warren Buffett Companies To Own In Right Now: Changyou.com Limited(CYOU)
Changyou.com Limited develops and operates online games in the People?s Republic of China. It involves in the development, operation, and licensing of massively multi-player online role-playing games (MMORPGs), which are interactive online games that might be played simultaneously by various game players. The company operates seven MMORPGs that include its in house developed Tian Long Ba Bu; and licensed Blade Online, Blade Hero 2, Da Hua Shui Hu, Zhong Hua Ying Xiong, Immortal Faith, and San Jie Qi Yuan. As of December 31, 2010, Changyou?s games in China had approximately 111.4 million aggregate registered accounts; 1.0 million aggregate peak concurrent users; and 2.7 million aggregate active paying accounts. The company was founded in 2003 and is based in Beijing, the People?s Republic of China. Changyou.com Limited is a subsidiary of Sohu.com Inc.
Advisors' Opinion:- [By Damian Illia]
In the video game industry no one is playing games. Users are seeking entertainment on all kinds of devices, and companies strive hard to stand out and profit in this shifting field. Competition might be stiff, but it�� a highly profitable business for those that make it to the next level. Electronic Arts (EA), Changyou.com (CYOU) and Activision Blizzard (ATVI) are three game developers with different, but interesting, prospects ahead. Let�� take a closer look at them and see if you��e up for play:
- [By Yiannis Mostrous]
Changyou.com (CYOU)
A subsidiary of Internet portal Sohu.com, video game developer Changyou.com specializes in massively multiplayer online role-playing games (MMORPG).
- [By Jake L'Ecuyer]
Changyou.com (NASDAQ: CYOU) shares tumbled 11.75percent to $26.02 after the company issued a weak Q1 guidance and announced the resignation of its CFO.
Hot Warren Buffett Companies To Own In Right Now: BreitBurn Energy Partners L.P.(BBEP)
BreitBurn Energy Partners L.P. engages in the acquisition, exploitation, and development of oil and gas properties in the United States. The company?s properties include natural gas, oil, and midstream assets comprising fields in the Antrim Shale in Michigan, and the New Albany Shale in Indiana and Kentucky; and fields in the Evanston and Green River basins in southwestern Wyoming, the Wind river and Big Horn basins in central Wyoming, the Powder River basin in eastern Wyoming, the Los Angeles basin in California, and fields in Florida?s Sunniland Trend. As of December 31, 2011, its total estimated proved reserves were 151.1 million barrels of oil equivalent. BreitBurn GP, LLC serves as the general partner to the company. BreitBurn Energy Partners L.P. was founded in 2006 and is headquartered in Los Angeles, California.
Advisors' Opinion:- [By Matt DiLallo]
It's one reason why the company has turned to aggressively growing its production organically. The production from LINN's oil and gas wells are in a state of continual production decline; it's just a fact of nature. In order to offset that decline, LINN and its industry peers like BreitBurn Energy Partners (NASDAQ: BBEP ) need to invest capital just to maintain current production levels to keep the distribution afloat. That's of course only part of the battle these companies face, and volatile commodity prices don't help much either. This is why both LINN and BreitBurn have turned to investing capital to grow production.
- [By Matt DiLallo]
Smelling blood in the water, these same short-sellers can continue to pick off similar targets. That's why I'd go out on a limb here and say that it wouldn't surprise to see the SEC launch an inquiry on Breitburn Energy Partners (NASDAQ: BBEP ) . It seemed that as soon as news hit that the SEC was looking into LINN, the same short-sellers that had targeted it then dubbed Breitburn as "LINN Energy Junior." Here again the accusations are scathing, as the company's distribution is being called "largely a mirage," which makes its units worth single digits. This has knocked the stock down over the past week, and the volatility isn't likely to abate anytime soon.
No comments:
Post a Comment